Welcome to our dedicated page for Ardelyx SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ardelyx, Inc. filings document a commercial-stage biopharmaceutical company with U.S. product revenue from IBSRELA and XPHOZAH and development activity centered on tenapanor and NHE3 inhibition. Form 8-K reports cover quarterly operating results, preliminary product sales, cash and investment updates, Regulation FD presentation materials, and other material-event disclosures tied to the company’s commercial and clinical programs.
Ardelyx proxy materials describe annual meeting proposals, director elections, say-on-pay matters, auditor ratification, executive compensation, board structure, and stockholder voting mechanics. Additional current reports record officer appointments, executive transitions, transition and separation agreements, compensatory arrangements, governance matters, and disclosure controls relevant to the company’s public-company reporting obligations.
Ardelyx, Inc. drew a new $50.0 million Term F Loan under its existing loan and security agreement with SLR Investment Corp. and other lenders to fund general corporate purposes and support strategic initiatives. The loan matures on July 1, 2030 and carries interest at 4.55% plus the greater of the 1‑month SOFR reference rate or 3.5%. Ardelyx is permitted to make interest‑only payments on this loan until maturity. The agreement includes customary events of default that could make the debt immediately due and allow the lenders to enforce on collateral, including the company’s cash, with default interest of an additional 4.0% per annum during any default period.
Ardelyx, Inc. Chief Patient Officer Laura A. Williams reported an open-market sale of 81,898 shares of common stock at a weighted average price of $5.989 per share. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2026, and the trades occurred in a price range from $5.97 to $6.0086. Following the sale, Williams directly holds 378,195 shares of Ardelyx common stock. On the same date, she also exercised a stock option to acquire 31,000 shares at an exercise price of $0.99 per share, reducing the outstanding option grant tied to those shares.
ARDELYX, INC. director Merdad Parsey reported equity compensation awards rather than open-market trades. He received 26,455 restricted stock units, each convertible into one share of common stock upon vesting, granted under the company’s Non-Employee Director Compensation Program.
He was also granted an option for 39,715 shares of common stock at an exercise price of $5.67 per share, expiring in 2036. The option vests in equal monthly installments over 12 months, with any unvested portion vesting in full at the next annual stockholder meeting, subject to continued service. Following these awards, he directly holds 83,746 shares of common stock.
Laura A. Williams submitted a notice of proposed sale under Form 144 for Common Stock. The filing lists 31,000 shares tied to an exercise of stock options dated 06/18/2026 and 50,898 shares associated with Restricted Stock Units dated 11/19/2022. The filing also discloses prior sales of 6,989 shares on 05/21/2026 for $43,803.56. The broker of record is Morgan Stanley Smith Barney LLC.
ARDELYX director Richard J. Rodgers received new equity awards as part of the Non-Employee Director Compensation Program. He acquired 26,455 restricted stock units and a stock option for 39,715 shares at $5.67 per share, bringing his direct holdings to 439,998 common shares.
The RSUs convert into one share each upon vesting. The option vests monthly over 12 months and any unvested portion accelerates at the next annual stockholder meeting, subject to his continued service.
ARDELYX, INC. director David M. Mott reported equity awards under the company’s Non-Employee Director Compensation Program. He received two grants of Common Stock totaling 46,737 shares at no cash cost and a stock option for 39,715 shares at an exercise price of $5.67 per share, expiring on June 16, 2036. Footnotes explain that some shares are held for entities associated with New Enterprise Associates and that restricted stock units and the option vest over time, with acceleration tied to the next annual stockholders’ meeting.
ARDELYX, INC. director Onaiza Cadoret-Manier received equity compensation on June 16, 2026. She was granted 26,455 restricted stock units, each convertible into one share of common stock under the Non-Employee Director Compensation Program, bringing her direct holdings to 178,156 common shares. She also received a stock option for 39,715 shares of common stock at an exercise price of $5.67 per share, expiring on June 16, 2036. The option vests in equal monthly installments over 12 months and any unvested portion accelerates at the next annual stockholders’ meeting, subject to continued service.
Ardelyx, Inc. director Muna Bhanji reported compensation-related equity grants. She received 26,455 restricted stock units, each convertible into one share of common stock upon vesting, under the company’s Non-Employee Director Compensation Program.
She was also granted options on 39,715 shares at an exercise price of $5.6700 per share, expiring on June 16, 2036. These options vest in 12 equal monthly installments and any remaining unvested portion will fully vest on the date of the next annual stockholders’ meeting, subject to continued service. Following these awards, she directly holds 163,808 shares of common stock.
Ardelyx director William C. Bertrand Jr. reported equity-based compensation grants. On June 16, 2026, he received 26,455 shares of common stock issued under Ardelyx’s Non-Employee Director Compensation Program after electing to take stock instead of cash fees.
He was also granted restricted stock units that convert into one share of common stock per unit upon vesting, issued under the same director program. In addition, he received a stock option for 39,715 shares at an exercise price of $5.67 per share, expiring June 16, 2036, which vests monthly with potential accelerated vesting at the next annual stockholders’ meeting.
ARDELYX, INC. director Robert B. Bazemore received equity compensation consisting of both shares and options. He was granted 26,455 restricted stock units, each convertible into one share of common stock upon vesting under the Non-Employee Director Compensation Program, bringing his direct holdings to 68,006 shares. He also received a stock option for 39,715 shares at an exercise price of $5.67 per share, vesting in 12 monthly installments and expiring on June 16, 2036, with unvested portions accelerating at the next annual stockholders’ meeting if he continues in service.